Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging
Autore:
Brenner, W; Klomp, HJ; Bohuslavizki, KH; Szonn, B; Kampen, WU; Henze, E;
Indirizzi:
Univ Kiel, Nucl Med Clin, D-24105 Kiel, Germany Univ Kiel Kiel Germany D-24105 iel, Nucl Med Clin, D-24105 Kiel, Germany Univ Kiel, Clin Gen Surg, D-24105 Kiel, Germany Univ Kiel Kiel Germany D-24105 iel, Clin Gen Surg, D-24105 Kiel, Germany Univ Hosp Eppendorf, Dept Nucl Med, Hamburg, Germany Univ Hosp Eppendorf Hamburg Germany rf, Dept Nucl Med, Hamburg, Germany
Titolo Testata:
EUROPEAN JOURNAL OF NUCLEAR MEDICINE
fascicolo: 12, volume: 26, anno: 1999,
pagine: 1567 - 1571
SICI:
0340-6997(199912)26:12<1567:LSOI>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
TL-201 SCINTIGRAPHY; METASTASES;
Keywords:
iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide; thallium-201; malignant melanoma; whole-body scintigraphy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Brenner, W Univ Kiel, Nucl Med Clin, Arnold Heller Str 9, D-24105 Kiel, Germany Univ Kiel Arnold Heller Str 9 Kiel Germany D-24105 el, Germany
Citazione:
W. Brenner et al., "Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging", EUR J NUCL, 26(12), 1999, pp. 1567-1571

Abstract

The aim of this prospective study was to assess the diagnostic value of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide (IBZM) whole-body imaging in comparison to thallium-201 scintigraphy in patients with metastatic malignant melanoma. Ten patients with suspected or proven locoregional metastases of malignant melanoma underwent whole-body scintigraphy both with Tl-201 and I-123-IBZM prior to scheduled surgery. Whole-body scans and planar scintigrams were acquired at 5 min and 30 min after injection of 100 MBq Tl-201 and at 10 min, 2 h, 4 h and 24 h after injection of 185 MBq I-123-IBZM. Ten out of 12 melanoma metastases, both melanotic and amelanotic as proven histologically, were detected by Tl-201 with a sensitivity of 83%. I-123-IBZM showed tracer uptake only in 3 melanotic metastases (sensitivity: 25%) with a maximum tumor-to-background ratio within 4 h, while none of the amelanotic metastases was IBZM-positive, All lesions localized by I-123-IBZM showed tracer uptake of Tl-201 as well, while Tl-201-negative lesions were also negative with IBZM. Because of the poor results of IBZM, the study was terminated after an interim evaluation of 10 patients. I-123-IBZM is a tracer with only moderate sensitivity in melanotic melanoma lesions, suggesting that this method has no clinical value as a routine investigation in melanoma patients. In comparison, our previous results with Tl-201 whole-body scintigraphy yielded 3 significantly higher sensitivity of about 80% in patients with locoregional melanoma metastases and may thus offer considerable potential in non-PET melanoma imaging.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 08:05:09